Emyria Limited

Equities

EMD

AU0000073645

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 02:10:37 2024-05-15 am EDT			5-day change	1st Jan Change
0.052 ^AUD	+4.00%		+13.04%	0.00%

Apr. 23	Emyria to Raise AU$2.3 Million via Placement	MT
Apr. 10	Emyria Launches Empax Center	MT

Emyria thrilled with new collaboration for MDMA-assisted PTSD therapy

March 08, 2023 at 03:31 pm EST

(via NewsDirect)

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company will collaborate with The Pax Centre (PAX) to develop a scalable care program for the safe provision of MDMA-assisted therapy for patients with treatment-resistant PTSD. This collaboration with Australia’s leading multidisciplinary, psychiatrist-led clinical service specialising in complex trauma treatment, feeds into EMD’s long-term goal to establish a network of trained therapists and psychiatrists to provide MDMA-assisted therapy.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Latest news about Emyria Limited

Emyria to Raise AU$2.3 Million via Placement	Apr. 22	MT
Emyria Launches Empax Center	Apr. 09	MT
Emyria's Second Psychiatrist Receives Authorized Prescriber Status from TGA	Apr. 04	MT
Emyria Signs Study Agreement for MDMA-Assisted Therapy; Shares Up 7%	Apr. 02	MT
Emyria Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Emyria Secures AU$2.5 Million R&D Tax Rebate for Fiscal Year 2023	Jan. 14	MT
Australian Medical Regulator Grants ‘Authorized Prescriber’ Status to Emyria’s Specialist Psychiatrist; Shares Soar 19%	Jan. 09	MT
Emyria Limited Appoints Greg Hutchinson as Director	Nov. 21	CI
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules	Nov. 15	MT
Emyria Limited Announces Board Changes	Nov. 12	CI
Emyria Secures Canadian Regulatory Clearance to Import MDMA to Australia; Shares Fall 3%	23-10-18	MT
Emyria Begins MDMA Therapy Trials on PTSD Patients	23-10-10	MT
Emyria Secures Local Supply of Psychedelic Drug for Upcoming Trial; Shares Rise 3%	23-09-20	MT
Emyria Completes Pax Center Acquisition	23-09-13	MT
Emyria Limited completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.	23-09-12	CI
Emyria Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Emyria Limited Announces Strategic Board Transition	23-08-20	CI
Emyria to Start Ketamine-Assisted Therapy Program for Depression	23-08-08	MT
Emyria Enrolls First Patient for Psychedelics-Assisted Trial	23-07-09	MT
Emyria to Acquire Psychological Trauma Care Firm	23-07-03	MT
Emyria Limited signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.	23-07-02	CI
Hawkish Central Bank, Muted Growth Concerns Send Australian Shares to Three-Day Losing Streak	23-06-08	MT
Emyria Secures Ethics Approval for Psychedelics-Assisted Trial; Shares Jump 8%	23-06-08	MT
Emyria to Raise AU$2.5 Million Via Share Placement	23-05-01	MT
Emyria Launches High-Potency Cannabidiol Capsule Product; Shares Rise 6%	23-04-24	MT

Chart Emyria Limited

Duration

Period

More charts

Company Profile

Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.

Sector

Healthcare Facilities & Services

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Hospitals, Clinics & Primary Care Services

	1st Jan change	Capi.
EMYRIA LIMITED	0.00%	12.14M
AIER EYE HOSPITAL GROUP CO., LTD.	-18.90%	16.5B
BANGKOK DUSIT MEDICAL SERVICES	+6.31%	12.81B
IHH HEALTHCARE	+3.98%	11.7B
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.65%	10.09B
ENCOMPASS HEALTH CORPORATION	+30.17%	8.75B
RAMSAY HEALTH CARE LIMITED	-3.46%	7.77B
MOUWASAT MEDICAL SERVICES COMPANY	+7.69%	6.42B
THE ENSIGN GROUP, INC.	+5.28%	6.67B
GLOBAL HEALTH LIMITED	+47.29%	4.54B

Hospitals, Clinics & Primary Care Services